Fiche centre
Neurologia Śląska Centrum Medyczne
Katowice — Poland
Essais liés8clinical trials
VilleKatowicelocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06392386
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Efgartigimod PH20 SC | Myasthénie | Phase 2/3 | NCT06392386 | ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| NMD670 | Myasthénie | Phase 2 | NCT06414954 | SYNAPSE-MG — Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Povetacicept | Myasthénie | Phase 2 | NCT07501702 | ETNA — A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | RECRUITING |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT05156398 | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects | RECRUITING |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |